Targets › PCSK9
20 programs from 20 companies in 69 trials: 25 Phase 3, 22 Phase 4, 16 Phase 2, 6 Phase 1; Cardiovascular, Metabolic and endocrine, Oncology; next expected readout Nov 2026.
Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. (UniProt, Q8NBP7)
Open in Phaseline: the race on PCSK9, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Inclisiran sodium PCSK9 mRNA rnai inhibitor | PCSK9 | Phase 4 | Hypercholesterolaemia; Plaque, Atherosclerotic; Coronary Heart Disease; Coronary Artery Disease … | Nov 2026 |
| First Affiliated Hospital of Xinjiang Medical University | PCSK9 inhibitors PCSK9 inhibitor | PCSK9 | Phase 4 | Coronary Artery Disease | Dec 2026 |
| University Medical Centre Ljubljana | Inclisiran PCSK9 mRNA RNAi inhibitor | PCSK9 | Phase 4 | Hypercholesterolemia | May 2027 |
| Amgen | Evolocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 4 | Cardiovascular Disease | May 2027 |
| Peking Union Medical College Hospital | Recaticimab PCSK9 inhibitor (monoclonal antibody) | PCSK9 | Phase 4 | Intracranial Atherosclerosis | Dec 2027 |
| Instituto de Investigación Marqués de Valdecilla | PCSK9 inhibitors PCSK9 inhibitor | PCSK9 | Phase 4 | Rheumatoid Arthritis (RA) | Apr 2031 |
| Merck & Co. (MSD) | Enlicitide Decanoate (MK-0616) PCSK9 inhibitor | PCSK9 | Phase 3 | Hyperlipidemia; Hypercholesterolemia; Arteriosclerosis; Lipoprotein(a) … | Dec 2026 |
| AstraZeneca | AZD0780 PCSK9 inhibitor | PCSK9 | Phase 3 | Heterozygous Familial Hypercholesterolaemia; Cardiovascular Disease; Dyslipidaemia | Jan 2027 |
| Innovent Biologics (Suzhou) | Tafolecimab (IBI306) Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 3 | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia; Acute Coronary Syndrome; Lung Cancer; Extensive-stage Small Cell Lung Cancer (ES-SCLC) … | Feb 2027 |
| Shanghai East Hospital | Recaticimab PCSK9 inhibitor | PCSK9 | Phase 3 | Stroke | Mar 2027 |
| Beijing Anzhen Hospital | Tafolecimab PCSK9 inhibitor | PCSK9 | Phase 3 | Aortic Stenosis | Dec 2027 |
| Icahn School of Medicine at Mount Sinai | Inclisiran PCSK9 mRNA RNAi inhibitor | PCSK9 | Phase 3 | Atherosclerotic Cardiovascular Disease | Jun 2032 |
| University of Oxford | Inclisiran PCSK9 mRNA RNAi inhibitor | PCSK9 | Phase 3 | Atherosclerotic Cardiovascular Disease | Dec 2049 |
| Hasten Biopharmaceutical | Lerodalcibep (HST101) Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 3 | Hypercholesterolemia | – |
| NewAmsterdam Pharma | evolocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 2 | Dyslipidemias; Type 1 Diabetes; Stroke, Ischemic; STEMI - ST Elevation Myocardial Infarction … | Nov 2026 |
| Regeneron Pharmaceuticals | Alirocumab Subtilisin/kexin type 9 inhibitor | PCSK9 | Phase 2 | Hypercholesterolemia; Dyslipidemias; Early PCSK9 Inhibitor on Ventricular Remodling; Acute Myocardial Infarction … | Dec 2026 |
| Beijing Chest Hospital, Capital Medical University | Recaticimab PCSK9 inhibitor | PCSK9 | Phase 2 | Non Small Cell Lung Cancer | Mar 2027 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Tafolecimab PCSK9-targeting monoclonal antibody | PCSK9 | Phase 2 | Bladder Urothelial Carcinoma | Jun 2028 |
| Verve Therapeutics | VERVE-102 Base-editing technology designed to disrupt PCSK9 gene expression in the liver | PCSK9 | Phase 1 | Heterozygous Familial Hypercholesterolemia | Oct 2027 |
| Monash University | STX-1150 mRNA-guided epigenome modulation targeting PCSK9 to reduce LDL-C | PCSK9 | Phase 1 | Elevated LDL-C and High Cholesterol | Dec 2028 |
Hypercholesterolemia (6) Atherosclerotic Cardiovascular Disease (4) Coronary Artery Disease (3) Cardiovascular Disease (3) Dyslipidemias (3) Aortic Stenosis (3) Hypercholesterolaemia (2) Acute Coronary Syndrome (2) Dyslipidaemia (2) Non Small Cell Lung Cancer (2) Hyperlipidemia (2) Healthy (2)
small molecule (7), mixed (5), other (3), antibody (3), protein or peptide (2)
Novartis (1) AstraZeneca (1) Shanghai East Hospital (1) First Affiliated Hospital of Xinjiang Medical University (1) Monash University (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1) Instituto de Investigación Marqués de Valdecilla (1) NewAmsterdam Pharma (1) Verve Therapeutics (1) Beijing Chest Hospital, Capital Medical University (1) Amgen (1) University of Oxford (1) Beijing Anzhen Hospital (1) Merck & Co. (MSD) (1) Icahn School of Medicine at Mount Sinai (1) Innovent Biologics (Suzhou) (1) Hasten Biopharmaceutical (1) University Medical Centre Ljubljana (1) Peking Union Medical College Hospital (1) Regeneron Pharmaceuticals (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.